StockTipsArenaBeta

BUY Gland Pharma Limited — Ashish Kyal, Waves Strategy Advisors

BUYGland Pharma Limited
Gland Pharma share price target & all analyst calls

byAshish Kyal, Waves Strategy AdvisorsHorizon: NA (inferred Swing (≤2wk))28 Oct 2026via CNBC Awaaz.

Entry₹3,052.2Inferred
Target₹3,230
Total upside +5.83%
Stop loss₹2,965-2.86% risk
CMP₹3,169.31d ago
Active+3.84%+1.92%upside left 4d left
Follow Ashish Kyal for new calls(28% target hit, 173 closed calls)Get alertsWatch GLAND for new buy/sell callsGet alertsSee 204 other Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 7 Nov, 5:24 pm IST
7 supporting2 neutral0 opposing
Supports the BUY call (7)

MACD above its signal line — bullish momentum

Technicals · macd·7 Nov · today

Gland Pharma Q2 Results: Net profit jumps 58% on strong business execution, CDMO revenue up 31%

NewsCnbc-Tv18·6 Nov · yesterday

(opens in new tab)

Gland Pharma reported Q2 FY27 financial results with a 23% year-on-year increase in revenue to 18,336 million and a 58% year-on-year increase in profit after tax to 2,908 million.

NSE · Press Release·6 Nov · yesterday

(opens in new tab)

Gland Pharma reported Q2 FY27 financial results with revenue increasing 23% year-on-year to ₹18,336 million and profit after tax growing 58% year-on-year to ₹2,908 million.

BSE · Company Update·6 Nov · yesterday

(opens in new tab)

Gland Pharma has received regulatory approval for its Methylprednisolone Acetate Injectable Suspension USP in both single and multiple dose vials.

BSE · Company Update·3 Nov · 4d ago

(opens in new tab)
Neutral / worth noting (2)

Gland Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.

NSE · Outcome of Board Meeting·6 Nov · yesterday

(opens in new tab)

Gland Pharma USFDA Inspection Dundigal Facility 2026

NewsGoogle News·23 Oct · 2w ago

(opens in new tab)
Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Gland Pharma

All analyst calls on Gland Pharma

More from Ashish Kyal, Waves Strategy Advisors

Every call and its outcome